Regulation of Protein Synthesis in Ventricular Myocytes by Vasopressin
THE ROLE OF SARCOPLASMIC/ENDOPLASMIC RETICULUM Ca2+ STORES*

Barbara A. Reilly, Margaret A. BrostromDagger , and Charles O. Brostrom

From the Department of Pharmacology, Robert Wood Johnson Medical School, Piscataway, New Jersey 08854

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Protein synthesis in H9c2 ventricular myocytes was subject to rapid inhibition by agents that release Ca2+ from the sarcoplasmic/endoplasmic reticulum, including thapsigargin, ionomycin, caffeine, and arginine vasopressin. Inhibitions were attributable to the suppression of translational initiation and were coupled to the mobilization of cell-associated Ca2+ and the phosphorylation of eIF2alpha . Ionomycin and thapsigargin produced relatively stringent degrees of Ca2+ mobilization that produced an endoplasmic reticulum (ER) stress response. Translational recovery was associated with the induction of ER chaperones and resistance to translational inhibition by Ca2+-mobilizing agents. Vasopressin at physiologic concentrations mobilized 60% of cell-associated Ca2+ and decreased protein synthesis by 50% within 20-30 min. The inhibition of protein synthesis was exerted through an interaction at the V1 vascular receptor, was imposed at physiologic extracellular Ca2+ concentrations, and became refractory to hormonal washout within 10 min of treatment. Inhibition was found to attenuate after 30 min, with full recovery occurring in 2 h. Translational recovery did not involve an ER stress response but rather was derived from the partial repletion of intracellular Ca2+ stores. Longer exposures to vasopressin were invariably accompanied by increased rates of protein synthesis. Translational inhibition by vasopressin, but not by Ca2+-mobilizing drugs, was both preventable and reversible by treatment with phorbol ester, which reduced the extent of Ca2+ mobilization occurring in response to the hormone. Larger and more prolonged translational inhibitions occurred after down-regulation of protein kinase C. This report provides the first compelling evidence that hormonally induced mobilization of sarcoplasmic/endoplasmic reticulum Ca2+ stores is regulatory upon mRNA translation.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Ca2+ sequestered by the endoplasmic reticulum (ER)1 is essential for optimal rates of protein synthesis occurring in nucleated mammalian cells (reviewed in Ref. 1). This control involves coupling of the rates of mRNA translation to those of protein translocation into the organelle for subsequent processing or folding. Depletion of ER sequestered Ca2+ to slow glycoprotein processing and transport competence, or introduction of a reducing environment to suppress ER processing of proteins with disulfide cross-links, results in the activation of the double-stranded RNA-activated protein kinase, the phosphorylation of eIF2alpha , the inhibition of eIF2B, and the slowing of translational initiation (2-6). An adaptive response, characterized by translational accommodation to continued depletion of ER Ca2+ stores by drugs such as ionomycin or thapsigargin or to the continued presence of a thiol-reducing agent, occurs over several hours. This adaptive response is dependent on increased expression of the ER resident chaperone, GRP78/BiP (1, 4, 7, 8). Inductions of this chaperone and of recovery from translational inhibition depend on activation of grp78 transcription and, in some cell types, a growth-promoting factor. The acute suppression of translational initiation by agents that inhibit ER protein processing, the induction of the ER chaperones GRP78 and GRP94, and the recovery of translational activity are characteristic of the "ER stress response" (1, 9, 10). Translational suppression, however, is not required for expression of the later events. Both GRP78 and translational tolerance can be induced by Ca2+-mobilizing or thiol-reducing agents at concentrations that do not suppress protein synthesis (7).

The physiologic significance of translational suppression by conditions provoking the ER stress response is unclear. However, Ca2+-mobilizing hormones, including epinephrine, angiotensin, and vasopressin, have been found to slow protein synthesis over several minutes in isolated hepatocytes (11-13). Inhibitions were reduced during incubations in Ca2+-depleted media and overturned at supraphysiologic Ca2+ concentrations (11). Corresponding reductions were observed in the polysomal contents of excised portions of perfused rat liver in response to hormones and manipulations of the Ca2+ content of the perfusing medium (14). It was proposed that hormonally induced changes in intracellular Ca2+ homeostasis provide a mechanism for regulating the rate of protein synthesis in normal hepatocytes. Given the transient viability and low synthetic rates of dispersed hepatocytes and the technical limitations associated with perfused rat liver, it has not been possible to correlate translational rates with changes in cell-associated Ca2+ or eIF2alpha phosphorylation, to examine the reversibility of hormonally imposed inhibitions, or to ascertain whether an adaptive response occurs during continuous hormonal treatments. Although cultured cells are better suited to such studies, cell lines exhibiting translational suppression in response to hormones that mobilize Ca2+ from the ER to the cytosol have not been identified.

We now report that H9c2 ventricular myocytes respond to drugs that deplete the sarcoplasmic/endoplasmic reticulum (S(E)R) of Ca2+ and to physiologic concentrations of arginine vasopressin with a rapid inhibition of mRNA translation at initiation. Inhibitions are coupled to the mobilization of cell-associated Ca2+ and to the phosphorylation of eIF2alpha . Ionomycin and thapsigargin produced relatively stringent degrees of Ca2+ mobilization in which translational recovery was associated with the induction of ER chaperones. Translational recovery from inhibition by vasopressin did not involve an ER stress response but derived instead from the partial repletion of intracellular Ca2+ stores. Inhibition of protein synthesis by vasopressin became refractory to hormonal washout within 10 min of treatment. These findings support the validity of hormonally mediated regulation of mRNA translation involving mobilization of Ca2+ sequestered within the S(E)R in ventricular myocytes.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- H9c2(2-1) rat embryonic ventricular myocytes were obtained from the American Type Culture Collection at passage number 12. Arginine vasopressin, lysine vasopressin, desmopressin, endothelin-1, angiotensin II, phenylephrine, caffeine, and phorbol 12-myristate 13-acetate (PMA) were purchased from Sigma. Ionomycin and thapsigargin were from Calbiochem. Monoclonal antibody to eIF2alpha was the gift of Dr. Lynn O'Brien, University of Rochester. Ampholines were purchased from Galliard-Schlesinger (pH 4-8) and from Oxford Glycosystems (pH 3.5-10). L-[4,5-3H]Leucine was purchased from Amersham Life Science, Inc., and [45Ca+2]CaCl2 was purchased from NEN Life Science Products.

General Methodology-- Stock H9c2 cells were propagated in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and subcultured before confluence. For experiments, monolayers were allowed to reach confluence after which cultures were maintained for 1 day in Dulbecco's modified Eagle's medium supplemented with 5% horse serum to promote differentiation of myoblasts into myotubes (15). Before treatments, cells were equilibrated for 5-15 min with serum-free Ham's F-10 medium modified to contain 25 mM leucine and 0.2 mM Ca2+. Leucine pulse incorporation was measured as described previously (16) for monolayers in multiwell trays (2.4 cm2/well) and for 15-min incubations. Incubations were conducted in triplicate and results are presented as the mean ± S.E. of values obtained. Findings were reproduced on at least two separate occasions. [35S]Methionine labeling, one-dimensional 7.5% polyacrylamide gel electrophoresis (SDS-PAGE) of detergent-solubilized extracts of methionine-labeled cells, and autoradiography were conducted as described previously (17). Ribosomal and polyribosomal size distributions were measured by density gradient centrifugation as described previously (18).

Measurement of Cell-associated 45Ca2+-- Cells in 12-well (4.8 cm2/well) plates were pre-equilibrated for 2 h in 1 ml of modified F-10 medium containing 0.2 mM Ca2+ and 45CaCl2 (0.02 Ci/mmol) before treatments. After treatments, monolayers were washed twice with 2 ml of ice-cold buffered saline containing 2.5 mM LaCl3, dissolved in 500 µl of 1% sodium dodecyl sulfate, and analyzed for radioactivity. 45Ca2+ in combination with 5 mM EGTA was added to non-equilibrated samples and the preparations washed and solubilized immediately to assess the contribution of extracellular 45Ca2+. These values (3% of experimental values) were subtracted from experimental values. Results, presented in nanomoles of cell-associated Ca2+/mg of protein, are expressed as the mean ± S.E. of values obtained for triplicate incubation samples. Findings were reproduced on at least two separate occasions.

Determination of the Phosphorylation State of eIF2alpha -- Duplicate monolayers (2.4 cm2) of multiwell trays were lysed at 40 °C in 200 µl of sample buffer containing 3% ampholines (4 parts pH 4-8 and 1 part pH 3-10), 0.4% Tween 20, 2% beta -mercaptoethanol, and 9.5 M urea. Lysates were then subjected to slab gel isoelectric focusing in the presence of 9.5 M urea as described (19) to separate the phosphorylated and non-phosphorylated forms of the alpha -subunit of eIF2. Gels were treated with 1 M Tris, pH 8.8, and blotted onto polyvinylidene difluoride membranes under basic conditions. Phosphorylated and non-phosphorylated eIF2alpha were immunodetected with monoclonal antibody to eIF2 and chemiluminescence as described previously (5). Films were scanned by UMAX Magic Scan version 1.3.3. Analysis of the relative amounts of phosphorylated and non-phosphorylated subunit was performed on a Macintosh Quadra 700 computer using the public domain NIH Image program.2

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Inhibition of Protein Synthesis in H9c2 Myocytes by Vasopressin: the Roles of S(E)R Ca2+ Stores and Protein Kinase C-- Agents that deplete ER Ca2+ stores inhibit protein synthesis in non-muscle cells in approximately 6-12 min (1-7, 17). Similar inhibitions were observed in H9c2 myocytes exposed for 30 min to agents that release Ca2+ from the sarcoplasmic reticulum or ER (Table I). The divalent cation ionophore, ionomycin, inhibited leucine incorporation and mobilized cell-associated Ca2+, with larger effects observed at 25 as compared with 5 nM drug. Thapsigargin (1 µM), an irreversible inhibitor of Ca2+ uptake by the S(E)R, mobilized 75% of cell-associated Ca2+ while inhibiting protein synthesis by 93%. Caffeine (5 mM), which releases Ca2+ from the sarcoplasmic reticulum of cardiac muscle (20), mobilized 45% of H9c2 cell-associated Ca2+ and inhibited leucine incorporation by 40%. Hormones that have been reported to increase cytosolic free Ca2+ ([Ca2+]i) in normal neonatal or H9c2 ventricular myocytes (21-25) were also examined for the ability to suppress protein synthesis and mobilize Ca2+ stores. Phenylephrine (10 µM) and epinephrine (data not shown) elicited marginal responses, whereas angiotensin II and endothelin-1 were ineffective. Arginine vasopressin (1 µM), however, mobilized approximately two thirds of the total cell-associated Ca2+ and suppressed protein synthesis by 45%. Inhibitions of protein synthesis in the range of 35-40% occurred at quite low arginine vasopressin concentrations (10 nM), maximized to slightly higher values (sime 50%) at 0.1-1 µM hormone, and were attributable to an interaction at the V1 vascular receptor (Fig. 1). Lysine vasopressin, a slightly less potent agonist selective for the V1 vascular receptor, elicited similar degrees of inhibition at 0.01-10 µM, whereas desmopressin, a long acting synthetic agonist selective for the V2 renal receptor, at identical concentrations did not affect leucine incorporation.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Effects of various Ca2+-mobilizing agents on leucine incorporation and cellular Ca2+ contents
H9c2 cells were pre-equilibrated for 2 h in F-10 medium containing 0.2 mM CaCl2 either with or without 4.5 µCi/ml 45CaCl2. Agents were then added at the indicated concentrations, and the incubation was continued for 30 min. Cell-associated Ca2+ was determined for prelabeled preparations, and pulse incorporation of [3H]leucine into proteins was determined for non-prelabeled preparations.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 1.   Inhibition of leucine incorporation by vasopressin analogs at varying concentrations. H9c2 cells were treated for 30 min in modified Ham's F-10 medium containing the indicated concentrations of arginine vasopressin (black-square), desmopressin (open circle ), or lysine vasopressin (down-triangle). [3H]Leucine was then added, and incorporation of labeled amino acid into protein was determined after 15 min.

The inhibition of leucine incorporation in H9c2 cells that developed in response to the mobilization of sequestered Ca2+ was readily reversed by restoration of the cation to the extracellular medium (Fig. 2). To generate Ca2+-depleted preparations, H9c2 cells were pretreated for 15 min in medium lacking Ca2+ and containing 0.1 µM ionomycin and 1 mM EGTA. Preparations were then washed with albumin-containing medium to remove ionophore (26) and equilibrated in medium containing 1 mM EGTA and graded increases in Ca2+. At Ca2+ concentrations in the physiological range (1 mM in excess of EGTA), leucine incorporation was stimulated approximately 8-10-fold. Activation of the V1 vascular receptor has been established to signal an increase in [Ca2+]i, which is dependent, in part, on the release of ER sequestered cation to the cytosol by inositol trisphosphate (27). The Ca2+ dependence of the vasopressin inhibition of protein synthesis was examined as a function of increasing extracellular concentrations of the cation (Fig. 2). Vasopressin had no effect on leucine incorporation at low extracellular Ca2+ concentrations but reduced incorporation at 1 mM free cation by half. Supraphysiologic (2-3 mM) extracellular Ca2+ concentrations did not reverse the inhibition attributable to vasopressin.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 2.   Extracellular Ca2+ concentration dependence of leucine incorporation in the absence and presence of arginine vasopressin. H9c2 cells were pretreated for 15 min in F-10 medium lacking Ca2+ and containing 1 mM EGTA and 100 nM ionomycin to deplete Ca2+ stores. Cells were washed twice with low Ca2+ medium lacking ionomycin and containing 2 mg/ml fatty acid free bovine serum albumin to bind ionophore. After addition of albumin-free medium containing 1 mM EGTA, preparations were adjusted with the indicated concentrations of Ca2+ and were incubated for 30 min. Incubations were continued for an additional 30 min in the absence (square ) or presence (black-square) of 10 µM arginine vasopressin. [3H]Leucine was then added, and pulse incorporation into protein was determined.

The time dependence of the inhibition of protein synthesis by vasopressin was determined for cells incubated for 2 h with 0.2 mM Ca2+, which is sufficient to maintain rates of leucine incorporation in untreated cells (Fig. 3). Within 20-30 min of hormone addition, maximal inhibition of leucine incorporation was observed. Thereafter, pulse incorporation rates were found to rise, with full recovery of activity observed at 2 h. The addition of EGTA in excess of Ca2+ produced declining pulse incorporation rates that plateaued at 50% of control values from 1-2 h. Vasopressin added in combination with the chelator provoked larger inhibitions of leucine incorporation (67% at 30 min), which were sustained through 2 h of incubation.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 3.   Time dependence of vasopressin inhibition of protein synthesis at low and high extracellular Ca2+ concentrations. H9c2 cells in F-10 medium containing 0.2 mM Ca2+ were treated for the indicated times with 10 µM arginine vasopressin (black-square), 1 mM EGTA (open circle ), or 10 µM arginine vasopressin and 1 mM EGTA (triangle ). [3H]Leucine was added, and pulse incorporation into protein was determined.

Activation of phospholipase C in response to occupation of V1 vascular receptors is associated with the intracellular generation of both inositol trisphosphate and diacylglycerol (27). The potential involvement of protein kinase C in translational regulation by vasopressin was therefore explored utilizing PMA as an activator of the enzyme. In control experiments, exposure of H9c2 cells to PMA for up to 30 min did not affect either leucine incorporation or cell-associated Ca2+ (data not shown). By 45 min, however, leucine incorporation tended to rise modestly. The effects of vasopressin on leucine incorporation were examined in cells that had been either pretreated for 15 min with 1 µM PMA or carried as untreated controls (Table II). PMA pretreatment was found to abolish the inhibition of leucine incorporation that occurred in untreated cells in response to the subsequent addition of vasopressin. PMA also fully reversed (within 5 min) pre-existing inhibitions of leucine incorporation attributable to vasopressin (data not shown). In contrast, suppression of leucine incorporation occurring in H9c2 cells treated with ionomycin, thapsigargin, sodium arsenite, or dithiothreitol or with heat shock (43 °C for 20 min), was neither prevented nor reversed by PMA (data not shown). Ca2+ mobilization in response to vasopressin was reduced, but not abolished, by PMA (Table II). Vasopressin mobilized approximately 37% of cell-associated Ca2+ in PMA-pretreated cells as compared with 50% release in non-treated cells; this degree of mobilization was completed within 10 min.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Leucine incorporation and cell-associated Ca2+ at various times of treatment with arginine vasopressin in the absence and presence of phorbol myristate acetate
H9c2 cells were pre-equilibrated for 2 h in F-10 medium containing 0.2 mM CaCl2 and in the absence or presence of 4.5 µCi/ml 45CaCl2. Cells were then pretreated for 15 min with either solvent (0.05% Me2SO) or phorbol myristate acetate (PMA, 1 µM). After incubation for the indicated times in the presence of vasopressin (AVP, 10 µM), cell-associated Ca2+ and pulse incorporation of [3H]leucine were determined.

Chronic exposure to phorbol ester was also employed to investigate the effects of protein kinase C down-regulation on vasopressin signaling. Conditions were chosen that are reported to produce down-regulation of the kinase in neonatal cardiomyocytes (28). H9c2 cells were pretreated for 16 h in complete growth medium with or without the addition of PMA. The time dependence of vasopressin inhibition of protein synthesis was then examined (Fig. 4). Non-pretreated preparations responded to hormone with a rapid suppression of protein synthesis that maximized at 20 min. Thereafter, pulse incorporation rates increased such that the 2-h values exceeded those of untreated controls. In preparations exposed chronically to PMA, vasopressin evoked larger (80%) inhibitions of leucine incorporation that were sustained for 40 min. Protein synthesis in these preparations recovered from inhibition by the hormone slowly, with only partial restoration of incorporation rates observed at 2 h. The protein kinase C inhibitors, calphostin C and chelerythrine, were tested in H9c2 cells at concentrations reported to inhibit the enzyme in vivo (29, 30). Each of these agents produced inhibition of leucine incorporation and the release of cell-associated Ca2+ within 30 min by indeterminant mechanisms (data not shown).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of chronic phorbol ester treatment on the recovery of protein synthesis from inhibition by arginine vasopressin. H9c2 cells were pretreated for 16 h in complete growth medium containing either 0.05% Me2SO (black-square) or 1 µM phorbol myristate acetate (square ). Pretreated preparations were incubated in serum-free F-10 medium containing 10 µM arginine vasopressin for the indicated times, and pulse incorporation of [3H]leucine into proteins was then determined.

Inhibition of Translational Initiation and Phosphorylation of eIF2alpha by Vasopressin-- The polyribosomal contents of H9c2 cells were examined after treatments with thapsigargin, vasopressin, PMA, and PMA in combination with vasopressin (Fig. 5). As anticipated, polysomes almost completely disappeared in response to thapsigargin, which slows initiation relative to peptide chain elongation in non-muscle cells (17). Vasopressin also reduced polysomal content, but not as dramatically as thapsigargin. Polyribosomes were preserved in incubations with PMA alone, and polysome disaggregation in response to vasopressin was reduced after brief pretreatment with the phorbol ester. To correct for potential differences in loading of gradients, the amounts of 80 S monosomes, small polysomes, and large polysomes were quantitated by absorbance at 254 nm and related to each other. For each treatment condition, the ratio of 80 S monosome:small polysome:large polysome was determined to be: control preparation, 30:10:10; thapsigargin, 67:3:0; vasopressin, 45:11:9; PMA, 24:10:10; PMA + vasopressin, 35:12:12. By this analysis, vasopressin caused 80 S monosomes to increase and polysomes to decrease, typical of a slowing of initiation. Large polysomes were reduced preferentially. By contrast, PMA, which stimulates amino acid incorporation, caused polysomes to accumulate at the expense of 80 S monosomes, consistent with increased rates of initiation. Effects of vasopressin were largely overturned by PMA, such that ribosomal profiles under this condition were similar to those of controls. Thapsigargin produced almost complete initiation blockade.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 5.   Polysome contents of H9c2 cells treated with thapsigargin, arginine vasopressin, phorbol myristate acetate, or both phorbol myristate acetate and arginine vasopressin. H9c2 cells in serum-free F-10 medium were treated for 30 min without drug (a), with 100 nM thapsigargin (b), with 10 µM arginine vasopressin (c), with 1 µM phorbol myristate acetate (d), or with both phorbol myristate acetate and arginine vasopressin (e). Lysates of variously treated preparations were then subjected to sucrose density gradient centrifugation for analysis of ribosomal size distributions. The arrow indicates the migration position of the 80 S monosome.

Suppression of translational initiation in non-muscle cells in response to drugs that deplete ER Ca2+ stores is attributable to the phosphorylation of the alpha -subunit of eIF2 by double-stranded RNA-activated protein kinase (1-4). The phosphorylated form of eIF2alpha is known to inhibit the GTP/GDP exchange factor, eIF2B, thereby preventing eIF2 recycling (19). Because eIF2B is usually present at much lower concentrations than eIF2, phosphorylations of 20-30% of the eIF-2alpha pool cause substantial inhibitions of eIF2B activity in most cell types (5, 6, 13, 31, 32). Addition of Ca2+-mobilizing drugs or vasopressin to H9c2 cells resulted in phosphorylation of eIF2alpha corresponding closely with the degree of inhibition of leucine incorporation (Fig. 6). In untreated preparations, 94-100% of eIF2alpha was present in the non-phosphorylated form (A, lanes 1 and 5; B, lanes 1 and 8; C, lanes 1 and 6). The strongest phosphorylations of eIF2alpha and concomitant suppressions of leucine incorporation occurred in response to 1 µM thapsigargin (A, lane 2). Caffeine at 5 mM (A, lane 3) and vasopressin at 10 µM (A, lane 4) were each less effective than thapsigargin in promoting eIF2alpha phosphorylation and inhibiting leucine incorporation. Increasing degrees of eIF2alpha phosphorylation and accompanying inhibitions of protein synthesis were observed in response to increasing concentrations of ionomycin (B, lanes 2-6). Within the same cell sampling, eIF2alpha was phosphorylated and protein synthesis was inhibited to comparable extents by 30 nM ionomycin (B, lane 4) and by 10 µM vasopressin (B, lane 7). Vasopressin produced eIF2alpha phosphorylation and inhibition of leucine incorporation at 15 and 30 min (C, lanes 2 and 3) that dissipated by 120 min (C, lane 4) of treatment. Brief exposure to PMA abolished eIF2alpha phosphorylation and translational suppression in response to 30 min of treatment with vasopressin (C, lane 5 as compared with lane 3).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of arginine vasopressin and other Ca2+-mobilizing agents on the phosphorylation state of eIF2alpha in H9c2 cells. Cells in serum-free F-10 medium were treated as described below. Preparations were denatured, subjected to slab gel isoelectric focusing, and immunoblotted for eIF2alpha . The migration positions of the authentic phosphorylated and non-phosphorylated subunits are indicated. The percent of eIF2alpha in the phosphorylated state was determined as described under "Experimental Procedures." Additional samples were taken for measurements of [3H]leucine pulse incorporation, with results provided as percent of the untreated control value. A, effects of brief treatments with thapsigargin, caffeine, or arginine vasopressin. Cells were incubated without drug (lanes 1 and 5), with 100 nM thapsigargin (Tg, lane 2), with 10 mM caffeine (CFN, lane 3), or with 10 µM arginine vasopressin (AVP, lane 4) for 30 min. B, effects of ionomycin at varying concentrations and of 10 µM vasopressin. Cells were treated without drug (lanes 1 and 8), with the indicated concentration of ionomycin (IM, lanes 2-6), or with 10 µM vasopressin (AVP, lane 7) for 30 min. C, effects of time of treatment with vasopressin and of treatment with phorbol myristate acetate before challenge with vasopressin. Cells were incubated without drug (lanes 1 and 6) or with 10 µM vasopressin for 15, 30, or 120 min (AVP, lanes 2, 3, and 4, respectively). An additional sample was pretreated with 1 µM PMA for 15 min and then challenged for 30 min with 10 µM vasopressin (lane 5).

Translational Recovery from Inhibition by Vasopressin-- Neither the acute inhibition of protein synthesis by hormone nor recovery from this inhibition was altered by actinomycin D at concentrations inhibitory to gene transcription, by rapamycin at concentrations that inhibit the ribosomal p70 S6 kinase (33), or by cAMP-elevating agents and analogs at concentrations that inhibit signal transduction dependent on Ras (34, 35) (data not shown). Earlier findings (see Table II and Figs. 3 and 4) were consistent with roles for protein kinase C activation and Ca2+ in overturning the inhibition of leucine incorporation by vasopressin. The degree to which H9c2 cells replenish their Ca2+ stores during recovery from translational inhibition by vasopressin was therefore examined. Leucine incorporation and cell-associated Ca2+ were measured after varying times of treatment with vasopressin (Fig. 7). Inhibition of incorporation paralleled the decline in cell-associated Ca2+ during the first 30 min of hormonal treatment. At 20-30 min, 60% of Ca2+ stores were mobilized and protein synthesis was inhibited 50%. Protein synthesis steadily recovered from inhibition thereafter, with full recovery being observed by 100 min. At 2 h of treatment, pulse incorporation rates were 20% higher than those in untreated controls. During the recovery period (30-100 min) cell-associated Ca2+ also increased but at slower rates than observed for leucine incorporation. Full recovery of pulse incorporation was associated with the restoration of approximately one-fourth of the cation initially mobilized.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 7.   Leucine incorporation and cell-associated Ca2+ at varying treatment times with arginine vasopressin. H9c2 cells were pre-equilibrated for 2 h in F-10 medium containing 0.2 mM CaCl2 and in the absence or presence of 4.5 µCi/ml 45CaCl2. Vasopressin (10 µM) was then added and the incubation continued for the indicated times. Cell-associated Ca2+ was determined for prelabeled preparations (open circle ), and pulse incorporation of [3H]leucine into proteins was determined for non-prelabeled preparations (black-square).

A variety of cell types respond to protracted ER Ca2+ mobilization with an ER stress response that includes the induction of GRP78 and the development of translational tolerance to Ca2+-mobilizing agents. H9c2 cells that had recovered from translational suppression by vasopressin over 2 h and corresponding untreated controls were examined for the development of such tolerance upon challenge with various concentrations of ionomycin, with thapsigargin at 1 µM, or with vasopressin at 10 µM (Table III). Comparable rates of leucine incorporation were observed for the hormonally pretreated and non-treated cells before challenge. Leucine incorporation in both preparations was reduced in a dose-dependent manner in response to increasing concentrations of ionomycin and was inhibited extensively in response to thapsigargin. A brief challenge with vasopressin, however, suppressed leucine incorporation in the non-treated controls by 68% but had no effect on incorporation in the vasopressin-pretreated preparations. Cell-associated Ca2+ was also determined for non-treated and vasopressin-pretreated preparations before and after challenge with Ca2+-depleting drugs (Table III). The Ca2+ contents of vasopressin-pretreated cells were 45% of those of non-treated controls. Ionomycin mobilized Ca2+ in a dose-dependent fashion from both the non-treated and the vasopressin-pretreated preparations. The Ca2+ contents of both preparations were reduced to comparably low values by 150 nM ionomycin and by 1 µM thapsigargin. After brief challenge with vasopressin, 65% of cell-associated Ca2+ was mobilized from the non-treated controls but no Ca2+ was released from the hormone-pretreated preparations.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Effects of Ca2+-mobilizing agents on leucine incorporation before and after recovery of protein synthesis from inhibition by arginine vasopressin
H9c2 cells were pre-equilibrated for 2 h in F-10 medium containing 0.2 mM CaCl2 and in the absence or presence of 4.5 µCi/ml 45CaCl2. Vasopressin (AVP, 10 µM) was added where indicated, and the incubation was continued for 2 h. Agents were then added at the indicated concentrations. After 30 min of treatments, cell-associated Ca2+ and pulse incorporation of [3H]leucine were determined.

To verify that H9c2 cells are capable of expressing the ER stress response, myocytes were incubated for 8 h at varying concentrations of ionomycin or with 0.5 µM thapsigargin. Preparations were washed to remove ionophore, and proteins were pulse-labeled with [35S]methionine and sampled for SDS-PAGE (7.5%) and autoradiography (Fig. 8). Preferential labeling of GRP78 and GRP94 was observed in response to treatments with 10-100 nM ionophore, with optimal labeling occurring at 30 nM (lanes c-f as compared with lane a). A modest increase in labeling of other proteins was also apparent in the treated preparations. Incubation with 5 nM ionomycin did not promote increased expression of the GRPs or stimulation of overall protein synthesis (lane b). The GRPs were also labeled preferentially in thapsigargin-pretreated preparations (lane g). Thapsigargin was not removed by the washing procedure, however, as evidenced by the decrease in overall protein labeling. Additional samples were pretreated for 2 h in the absence and presence of vasopressin before incubations in the absence or presence of ionomycin (30 nM). Preparations were washed and proteins were pulse-labeled and analyzed by SDS-PAGE and autoradiography as above (Fig. 8). Although labeling of most cellular proteins was modestly increased in the vasopressin-treated sample, expression of the GRPs was not selectively increased by the hormone (lane k as compared with lane i). No selective labeling of the GRPs was observed during shorter incubations with vasopressin (data not shown). However, pretreatment with vasopressin followed by incubation with ionomycin resulted in greater pulse-labeling of GRP78 and GRP94 than was observed in samples incubated with ionophore alone (lane l as compared with lane j).


View larger version (89K):
[in this window]
[in a new window]
 
Fig. 8.   Induction of the Glucose Regulated Proteins in H9c2 cells by Ca2+-mobilizing agents. H9c2 cells in F-10 medium were incubated without drug (lanes a and h), with 5, 10, 15, 30, or 100 nM ionomycin (lanes b-f, respectively), or with 1 µM thapsigargin (lane g) for 8 h. In a separate experiment, cells were incubated for 2 h in F-10 medium with (lanes k and l) or without (lanes i and j) 1 µM vasopressin followed by 8 h in the absence (lanes i and k) or presence (lanes j and l) of 30 nM ionomycin. Cells were washed with medium lacking drugs and containing 2 mg/ml fatty acid free bovine serum albumin. Proteins were then pulse-labeled by incubation for 30 min in medium containing 5 µM methionine and 20 µC/ml [35S]methionine, and lysates were analyzed by SDS-PAGE (7.5%) and autoradiography. The migration position of molecular weight markers is indicated on the ordinate in kDa.

To ascertain whether translational tolerance to inhibition by vasopressin accompanies induction of the GRPs, H9c2 cells were pretreated for 8 h in the absence or presence of ionomycin or thapsigargin (irreversible). Preparations were washed and then challenged with ionomycin at increasing concentrations, with thapsigargin, or with vasopressin. After 30 min of treatments, samples were analyzed by measurement of leucine pulse incorporation (Table IV). Incorporation in the control preparations was inhibited in the typical fashion by ionophore, thapsigargin, and vasopressin. By contrast, protein synthesis in ionomycin-pretreated preparations was markedly resistant to suppression by these agents. No inhibition by ionophore was observed except at the highest (150 nM) concentration tested, and 10 µM vasopressin was ineffective. Although thapsigargin suppressed incorporation in ionomycin-pretreated preparations, the extent of this suppression was not as great as in controls. Samples pretreated with thapsigargin had somewhat lower synthetic rates as compared with untreated controls, but protein synthesis was completely unaffected after challenge with ionomycin at all concentration tested, with thapsigargin, or with vasopressin.

                              
View this table:
[in this window]
[in a new window]
 
Table IV
Tolerance to translational inhibition by vasopressin and other Ca2+-mobilizing agents after expression of the GRPs
H9c2 cells were incubated for 8 h in serum-free F-10 medium in the absence of drug or with 300 nM ionomycin or 1 µM thapsigargin. Cells were washed twice with medium lacking drugs and containing 2 mg/ml fatty acid-free bovine serum albumin. Agents were then added at the concentrations indicated below. After 30 min of treatments, pulse incorporation of [3H]leucine into proteins was determined.

Reversibility of Translational Inhibition by Vasopressin-- Physiologic responses to vasopressin are known to persist despite receptor internalization, which, depending on cell type, at 37 °C occurs within 3-20 min of receptor occupation (36-38). It was nonetheless unclear whether the translational inhibition imposed by vasopressin in H9c2 cells was reversible or persisted upon removal of the hormone. Cells were therefore treated with vasopressin for 0, 2, 5, 10, 15, or 20 min, and the preparations were washed three times with medium lacking hormone. Washed preparations were then incubated for 30 min in fresh medium lacking or containing vasopressin, followed by measurements of leucine pulse incorporation (Table V). Inhibitions of protein synthesis attributable to vasopressin ranged from 55% at 2 min to 69% at 20 min of treatment. These inhibitions were reversible by removal of hormone at 2 and 5 min of treatment, but thereafter were irreversible.

                              
View this table:
[in this window]
[in a new window]
 
Table V
Reversibility of translational inhibition by vasopressin
H9c2 cells were treated with vasopressin (100 nM) for the indicated times. Medium was then removed, and the cells were washed three times with medium lacking vasopressin. Medium lacking or containing hormone was then added as indicated. After 30 min, medium was again replaced with fresh medium lacking or containing vasopressin, and pulse incorporation of [3H]leucine into protein was determined.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Although Ca2+ sequestration by the ER has been previously established to maintain optimal rates of translational initiation in mammalian cells, the drugs utilized to mobilize the cation invariably led to the development of an ER stress response. This report provides the first compelling evidence that hormonally induced mobilization of S(E)R Ca2+ stores is regulatory upon translation in that it is receptor-mediated, observable at physiological extracellular Ca2+ concentrations, and reversible without the generation of a stress response. Translational inhibitions coinciding with mobilization of S(E)R Ca2+ stores of H9c2 ventricular myocytes were imposed by arginine vasopressin at concentrations that raise [Ca2+]i in normal cardiomyocytes (39, 40). Inhibitions were exerted as a consequence of a hormonal interaction at the V1 vascular receptor (39, 40), the receptor expressed in normal cardiac tissue (27). Vasopressin exerted a persistent, albeit decreasing, inhibition of translation for periods of 1-2 h. This result was not surprising in that vasopressin receptors are known to undergo internalization within 3-20 min in various tissues after hormonal binding. The physiologic effects of the hormone persist after internalization (27). The ability of the hormone to signal translational inhibition in H9c2 cells was reversible by washing for only several minutes. Circulating vasopressin has a relatively long half-life (approximates 20 min) and undergoes degradation in the liver and kidney but not in the pulmonary circulation (41).

Inhibition of the translational process in H9c2 cells by treatment with vasopressin involved imposition of the same mechanisms as those exerted by ionomycin, which destroys intracellular Ca2+ gradients, and thapsigargin, which blocks the Ca2+-ATPase of the S(E)R. Vasopressin, like ionomycin and thapsigargin (1-7, 17), slowed translation at the initiation step and caused eIF2alpha to become phosphorylated. Phosphorylation of this initiation factor correlated closely with hormonal inhibitions of protein synthesis under all experimental conditions tested. As has been observed invariably with agents that inhibit translational initiation by mobilizing ER Ca2+ stores (1, 4, 5, 7, 8, 17), protein synthesis in cells expressing increased concentrations of ER chaperones was tolerant to inhibition by vasopressin. The mechanism through which vasopressin caused Ca2+ stores of H9c2 cells to be mobilized was not explored. Unlike depletion of Ca2+ stores by thapsigargin or ionophores, Ca2+ depletion in response to vasopressin began to attenuate after 30 min. Attenuation presumably involved either decreased production of, enhanced degradation of, or declining responsiveness to intracellular messenger(s) that mobilize Ca2+ from the S(E)R to the cytosol. Vasopressin acting at V1 vascular receptors of various tissues is established to signal the activation of phospholipase C and the generation of inositol trisphosphate during the first few min of treatment (27). Inositol trisphosphate is widely documented as an intracellular mediator of hormone-dependent Ca2+ mobilization, although cyclic ADP-ribose has also been advanced as a putative physiologic regulator of ryanodine-sensitive Ca2+-dependent release processes in intact mammalian systems, including heart (20, 42, 43). Mediation of the Ca2+-mobilizing effects of vasopressin by cyclic ADP-ribose in H9c2 cells would be consistent with the actions of caffeine, a pharmacologic activator of the cardiac ryanodine receptor (20), in promoting Ca2+ release, translational suppression, and eIF2alpha phosphorylation. Caffeine affects these parameters in a quantitatively similar manner to vasopressin. Eicosanoids have also been proposed to mediate the Ca2+-mobilizing actions of vasopressin in smooth muscle cells (27).

As in various non-muscle cell types (1, 4, 5, 7, 8, 17), recovery of H9c2 cells from translational inhibition by Ca2+-mobilizing drugs was contingent upon induction of expression of ER chaperones. In contrast, recovery from translational inhibition by vasopressin depended on partial re-accumulation of Ca2+ and, most probably, the activation of protein kinase C. Indirect evidence, including abolition of vasopressin inhibition in the presence of a phorbol ester and prolonged inhibition of translation under conditions wherein the enzyme is known to be down-regulated, supports a role for protein kinase C in this event. Both calphostin C and chelerythrine at concentrations used widely to investigate the involvement of protein kinase C in various processes, produced the mobilization of Ca2+ and the phosphorylation of eIF2alpha . It was not possible to determine whether the effects of these inhibitors derived from inhibition of protein kinase C activity or from actions at other sites. Any action through protein kinase C would imply that the enzyme is partially coupled to translational rates in H9c2 cells in the absence of hormonal influences. No other requirements for recovery of translational activity could be identified. Other protein kinases that are signaled in response to vasopressin, such as ribosomal S6 kinases (44) and mitogen-activated protein kinase (45, 46), could not be implicated. Although activation of V1 vascular receptors is known to signal increased transcription of the immediate early genes (27), transcriptional events were not required for translational recovery.

Recovery from translational inhibition by vasopressin was associated with partial, rather than full, restoration of cell-associated Ca2+, presumably at the S(E)R. Information is lacking regarding whether H9c2 or other cell types possess critical ER or S(E)R "pools" or subcompartments of Ca2+ supporting translation. Translational inhibition in GH3 and HepG2 cells occurs at somewhat greater degrees of ER Ca2+ depletion than are required to impede protein processing within the organelle (1, 7, 26). Inhibition of protein processing invariably appears to trigger the phosphorylation of eIF2alpha in response to Ca2+ depletion. Ca2+ re-accumulation in H9c2 cells after 2 h of vasopressin treatment, therefore, may restore ER function sufficiently that protein synthesis can resume. PMA, presumably by activating protein kinase C, reduced the degree to which vasopressin lowered cell-associated Ca2+.

Although ionomycin (30 nM) and vasopressin (10 µM) generated comparable degrees of cation mobilization and eIF2alpha phosphorylation over 30 min, only ionomycin produced a subsequent ER stress response. The ionophore at 30 nM clearly signaled comparable degrees of GRP78 induction and translational tolerance in H9c2 cells to those observed in other cell types (1, 4, 5, 7-10, 17). Continued exposures to either ionomycin or thapsigargin elicited strong inductions of GRP78 and GRP94 and development of translational tolerance to ER stressors in H9c2 cells without additional requirements for auxiliary promoters (serum, PMA, growth factors, cAMP analogs) observed in GH3, NIH-3T3, and myeloma cells (1, 4, 5, 7, 17). Vasopressin treatment of H9c2 cells differs from other Ca2+-mobilizing drugs by permitting partial recovery of cell-associated Ca2+ after 30 min. This recovery, which is accompanied by increasing rates of protein synthesis, may sufficiently restore S(E)R function as to ablate the development of an ER stress response.

Vasopressin exerts inotropic actions on cardiovascular performance that was until recently, attributed to hormonal effects at the vasculature and kidney. The hormone is now appreciated to stimulate lipid metabolism in perfused hearts (47) and H9c2 cells (24), to increase [Ca2+]i in cardiomyocytes (39), to potentiate ventricular L-type currents via V1 vascular receptor stimulation (40), and to cause atrial natriuretic factor to be secreted from cardiomyocytes (48). The translational suppression observed in H9c2 cells in response to vasopressin provides additional evidence that the heart is directly targeted by this hormone. The functional significance of the short-term suppression of ventricular protein synthesis accompanying mobilization of cell-associated Ca2+ by the hormone remains to be clarified. Both muscle contraction, which is supported by [Ca2+]i, and mRNA translation, which is supported by S(E)R sequestered Ca2+, are energy-intensive processes. Reduced translation accompanying release of S(E)R Ca2+ to the cytosol may therefore function to divert ATP production toward supporting increased contractile activity. In addition to its antidiuretic actions, vasopressin serves broadly as a growth factor and, depending on cell type, can promote either hypertrophy or hyperplasia (27). Induction of specific gene expression and enhanced rates of protein synthesis are both required for growth responses to vasopressin. In support of a growth-promoting effect of vasopressin on H9c2 cells, prolonged exposure to the hormone was invariably accompanied by increased rates of amino acid incorporation into protein. It is anticipated that H9c2 cells should provide a highly useful model system for investigating both the acute and the chronic effects of vasopressin on the biochemistry and physiology of ventricular myocytes.

    FOOTNOTES

* This work was supported by a research award from the American Diabetes Association.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Department of Pharmacology, UMDNJ-Robert Wood Johnson Medical School, 675 Hoes Ln., Piscataway, NJ 08854. Tel.: 732-235-4086; Fax: 732-235-4073; E-mail: brostrom{at}umdnj.edu.

1 The abbreviations used are: ER, endoplasmic reticulum; S(E)R, sarcoplasmic/endoplasmic reticulum; [Ca2+]i, cytosolic free Ca2+ concentration; eIF, eukaryotic initiation factor; GRP, glucose-regulated stress protein; GRP78/BiP, glucose-regulated stress protein 78 or immunoglobulin heavy chain binding protein; PMA, phorbol 12-myristate 13-acetate; PAGE, polyacrylamide gel electrophoresis.

2 Software was developed at the National Institutes of Health and is available from the Internet by anonymous ftp from zippy.nimh.nih.gov or on floppy disk from NTIS, 5285 Port Royal Rd., Springfield, VA 22161 (PB95-500195GEI).

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Brostrom, C. O., and Brostrom, M. A. (1998) Prog. Nucleic Acids Res. Mol. Biol. 58, 79-125[Medline] [Order article via Infotrieve]
  2. Prostko, C. R., Dholakia, J. N., Brostrom, M. A., Brostrom, C. O. (1995) J. Biol. Chem. 270, 6211-6215[Abstract/Free Full Text]
  3. Srivastava, S. P., Davies, M. V., and Kaufman, R. J. (1995) J. Biol. Chem. 270, 16619-16624[Abstract/Free Full Text]
  4. Brostrom, C. O., Prostko, C. R., Kaufman, R. J., Brostrom, M. A. (1996) J. Biol. Chem. 271, 24995-25002[Abstract/Free Full Text]
  5. Prostko, C. R., Brostrom, M. A., Malara, E. M., Brostrom, C. O. (1992) J. Biol. Chem. 267, 16751-16754[Abstract/Free Full Text]
  6. Kimball, S. R., and Jefferson, L. S. (1992) Am. J. Physiol. 263, E958-E964[Medline] [Order article via Infotrieve]
  7. Brostrom, M. A., Prostko, C. R., Gmitter, D., and Brostrom, C. O. (1995) J. Biol. Chem. 270, 4127-4132[Abstract/Free Full Text]
  8. Morris, J. A., Dorner, A. J., Edwards, C. A., Hendershot, L. M., Kaufman, R. J. (1997) J. Biol. Chem. 272, 4327-4334[Abstract/Free Full Text]
  9. Lee, A. S. (1992) Curr. Opin. Cell Biol. 4, 267-273[Medline] [Order article via Infotrieve]
  10. Little, E., Ramakrishnan, M., Roy, B., Gazit, G., and Lee, A. S. (1994) Crit. Rev. Eukaryotic Gene Exp. 4, 1-18[Medline] [Order article via Infotrieve]
  11. Brostrom, C. O., Bocckino, S. B., Brostrom, M. A., Galuska, E. M. (1986) Mol. Pharmacol. 29, 104-111[Abstract]
  12. Menaya, J., Parrilla, R., and Ayuso, M. S. (1988) Biochem. J. 254, 773-779[Medline] [Order article via Infotrieve]
  13. Kimball, S. R., and Jefferson, L. S. (1990) J. Biol. Chem. 265, 16794-16798[Abstract/Free Full Text]
  14. Chin, K.-V., Cade, C., Brostrom, M. A., Brostrom, C. O. (1988) Int. J. Biochem. 20, 1313-1319[Medline] [Order article via Infotrieve]
  15. Schopf, G., Rumpold, H., and Muller, M. M. (1986) Biochim. Biophys. Acta 884, 319-325[Medline] [Order article via Infotrieve]
  16. Brostrom, C. O., Bocckino, S. B., and Brostrom, M. A. (1983) J. Biol. Chem. 258, 14390-14399[Abstract/Free Full Text]
  17. Wong, W. L., Brostrom, M. A., Kuznetsov, G., Gmitter-Yellen, D., and Brostrom, C. O. (1993) Biochem. J. 289, 71-79[Medline] [Order article via Infotrieve]
  18. Chin, K.-V., Cade, C., Brostrom, C. O., Galuska, E. M., Brostrom, M. A. (1987) J. Biol. Chem. 262, 16509-16514[Abstract/Free Full Text]
  19. Scorsone, K. A., Panniers, R., Rowlands, A. G., Henshaw, E. C. (1987) J. Biol. Chem. 262, 14538-14543[Abstract/Free Full Text]
  20. Rakovic, S., Galione, A., Ashamu, G., Potter, B. V. L., Terrar, D. A. (1996) Curr. Biol. 6, 989-996[Medline] [Order article via Infotrieve]
  21. Komuro, I., and Yazaki, Y. (1993) Annu. Rev. Physiol. 55, 55-75[CrossRef][Medline] [Order article via Infotrieve]
  22. Decker, R. S., Cook, M. G., Behnke-Barclay, M., and Decker, M. L. (1995) Circ. Res. 77, 544-555[Abstract/Free Full Text]
  23. Bogoyevitch, M. A., and Sugden, P. H. (1996) Int. J. Biochem. Cell. Biol. 28, 1-12[CrossRef][Medline] [Order article via Infotrieve]
  24. Tran, K., Zha, X., Chan, M., and Choy, P. C. (1995) Mol. Cell. Biochem. 151, 69-75[Medline] [Order article via Infotrieve]
  25. Tran, K., Man, R. Y., and Choy, P. C. (1995) Biochim. Biophys. Acta 1259, 283-290[Medline] [Order article via Infotrieve]
  26. Kuznetsov, G., Brostrom, M. A., and Brostrom, C. O. (1992) J. Biol. Chem. 267, 3932-3939[Abstract/Free Full Text]
  27. Thibonnier, M. (1992) Regul. Pept. 38, 1-11[CrossRef][Medline] [Order article via Infotrieve]
  28. Johnson, J. A., Adak, S., and Mochly-Rosen, D. (1995) Life Sci. 57, 1027-1038[CrossRef][Medline] [Order article via Infotrieve]
  29. Kobayashi, E., Nakano, H., Morimoto, M., and Tamaoki, T. (1989) Biochem. Biophys. Res. Commun. 159, 548-553[Medline] [Order article via Infotrieve]
  30. Jarvis, W. D., Turner, A. J., Povirk, L. F., Traylor, R. S., Grant, S. (1994) Cancer Res. 54, 1707-1714[Abstract]
  31. Safer, B. (1983) Cell 33, 7-8[Medline] [Order article via Infotrieve]
  32. Rowlands, A. G., Panniers, R., and Henshaw, E. C. (1988) J. Biol. Chem. 263, 5526-5533[Abstract/Free Full Text]
  33. Price, D. J., Grove, J. R., Calvo, V., Avruch, J., and Bierer, B. E. (1992) Science 257, 973-977[Medline] [Order article via Infotrieve]
  34. Cook, S. J., and McCormick, F. (1993) Science 262, 1069-1072[Medline] [Order article via Infotrieve]
  35. Burgering, B. M. Th., Pronk, G. J., van Weeren, P. C., Chardin, P., Bos, J. L. (1993) EMBO J. 12, 4211-4220[Abstract]
  36. Fishman, J. B., Dickey, B. F., Bucher, N. L. R., Fine, R. E. (1985) J. Biol. Chem. 260, 12641-12646[Abstract/Free Full Text]
  37. Lutz, W., Salisbury, J. L., and Kumar, R. (1991) Am. J. Physiol. 261, F1-F13[Abstract]
  38. Briner, V. A., Williams, B., Tsai, P., and Schrier, R. W. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2854-2858[Abstract]
  39. Zu, Y. J., and Gopalakrishnan, V. (1991) Circ. Res. 69, 239-245[Abstract]
  40. Zhang, S., Hirano, Y., and Hiraoka, M. (1995) Circ. Res. 76, 592-599[Abstract/Free Full Text]
  41. Culpepper, R. M., Hebert, S. C., and Andreoli, T. E. (1985) in Textbook of Endocrinology (Wilson, J. D., and Foster, D. W., eds), p. 619, W. B. Saunders, Philadelphia
  42. Meszaros, L. G., Bak, J., and Chu, A. (1993) Nature 364, 76-79[CrossRef][Medline] [Order article via Infotrieve]
  43. Lee, H. C., Galione, A., and Walseth, T. F. (1994) Vitam. Horm. 48, 199-257[Medline] [Order article via Infotrieve]
  44. Granot, Y., Erikson, E., Fridman, H., Van Putten, V., Williams, B., Schrier, R. W., Maller, J. L. (1993) J. Biol. Chem. 268, 9564-9569[Abstract/Free Full Text]
  45. Nishioka, N., Hirai, S., Mizuno, K., Osada, S., Suzuki, A., Kosaka, K., and Ohno, S. (1995) FEBS Lett. 377, 393-398[CrossRef][Medline] [Order article via Infotrieve]
  46. Aharonovitz, O., and Granot, Y. (1996) J. Biol. Chem. 271, 16494-16499[Abstract/Free Full Text]
  47. Palazzo, A. J., Malik, K. U., and Weis, M. T. (1991) Am. J. Physiol. 260, H604-H612[Abstract/Free Full Text]
  48. Van der Bent, V., Church, D. J., Vallotton, M. B., Meda, P., Kem, D. C., Capponi, A. M., Lang, U. (1994) Am. J. Physiol. 266, H597-H605[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.